SANA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.858 SEK | +3.22% |
|
+0.43% | -53.67% |
| Mar. 01 | Sana Biotechnology Shares Rise as Q4 Non-GAAP Net Loss Narrows | MT |
| Mar. 01 | Sector Update: Health Care Stocks Edge Higher Premarket Friday | MT |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 746.4 | 730.2 | 552.1 | 191.2 | 206.7 | 206.7 | - |
| Enterprise Value (EV) 1 | 697.7 | 691.4 | 552.1 | 191.2 | 257.1 | 206.7 | 206.7 |
| P/E ratio | -17.4 x | - | -1.34 x | -0.78 x | - | - | - |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 13.6 x | 270 x | - | 12.5 x | 15.3 x | 3.33 x | 3.69 x |
| EV / Revenue | 13.6 x | 270 x | - | 12.5 x | 15.3 x | 3.33 x | 3.69 x |
| EV / EBITDA | -13.9 x | -7.18 x | - | -0.88 x | -3.6 x | -7.65 x | -6.46 x |
| EV / FCF | -31.1 x | -7.16 x | - | -0.68 x | -3 x | -5.91 x | -10.9 x |
| FCF Yield | -3.22% | -14% | - | -148% | -33.3% | -16.9% | -9.19% |
| Price to Book | 18.9 x | 12.2 x | - | - | - | - | - |
| Nbr of stocks (in thousands) | 23,324 | 28,413 | 62,386 | 62,386 | 111,238 | 111,238 | - |
| Reference price 2 | 32.00 | 25.70 | 8.850 | 3.065 | 1.858 | 1.858 | 1.858 |
| Announcement Date | 2/21/19 | 2/7/20 | 2/24/22 | 2/23/23 | 2/29/24 | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 54.9 | 2.7 | - | 15.28 | 16.84 | 62 | 56 |
| EBITDA 1 | -53.57 | -101.7 | - | -217.9 | -71.41 | -27 | -32 |
| EBIT 1 | -54.2 | -103.9 | - | -225.7 | -81.06 | -29 | -38 |
| Operating Margin | -98.72% | -3,848.15% | - | -1,476.93% | -481.38% | -46.77% | -67.86% |
| Earnings before Tax (EBT) 1 | -48.29 | -83.5 | - | -252 | -104.3 | -37 | -43 |
| Net income 1 | -41.1 | -75.8 | -410.9 | -245.4 | -95.81 | -37 | -43 |
| Net margin | -74.86% | -2,807.41% | - | -1,605.42% | -568.94% | -59.68% | -76.79% |
| EPS | -1.840 | - | -6.590 | -3.930 | - | - | - |
| Free Cash Flow 1 | -24.03 | -102 | - | -282.5 | -85.66 | -35 | -19 |
| FCF margin | -43.77% | -3,776.19% | - | -1,848.6% | -508.67% | -56.45% | -33.93% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 2/21/19 | 2/7/20 | 2/24/22 | 2/23/23 | 2/29/24 | - | - |
1SEK in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | 48.7 | 38.8 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -24 | -102 | - | -283 | -85.7 | -35 | -19 |
| ROE (net income / shareholders' equity) | -107% | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | -62.5% | -84.6% | - | - | - | - | - |
| Assets 1 | 65.79 | 89.55 | - | - | - | - | - |
| Book Value Per Share | 1.690 | 2.100 | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | 1.11 | 3.49 | - | - | - | - | - |
| Capex / Sales | 2.02% | 129.19% | - | - | - | - | - |
| Announcement Date | 2/21/19 | 2/7/20 | 2/24/22 | 2/23/23 | 2/29/24 | - | - |
1SEK in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -53.67% | 18.85M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- SANION Stock
- Financials SANA AB
